The objective of this study was to assess the cost effectiveness of a continuous combined oral preparation of norethisterone (norethindrone) acetate and ethinylestradiol (NA/EE) [FemHRT] as both a first-line and second-line therapy for menopausal women.
Clinical Epidemiology, Ottawa Health Research Institute, Ottawa Hospital Department of Medicine and Epidemiology, University of Ottawa, Ottawa, Ontario, Canada. dcoyle@ohri.ca
